NewsFeed Voices Science Insight Innovation
January, 2026
January 2026
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Maxime Dely – The French Transfusion landscape is Evolving
Maxime Dely/LinkedIn
Nov 13, 2025, 01:14

Maxime Dely – The French Transfusion landscape is Evolving

Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, shared a post on LinkedIn:

”The French transfusion landscape is evolving

As hospital needs change and health sovereignty becomes a national priority, the 2024 Annual Report of the French Blood Establishment (EFS) highlights a major transformation in the country’s transfusion system.

Red blood cell use continues to decline

The number of red blood cell (RBC) units issued keeps decreasing:

  • 2,081,938 units delivered in 2024
  • -3.4 % compared to 2023

This trend reflects:

• More efficient use of transfusion indications
• Improved patient blood management
• Optimization of clinical practices

Plasma takes center stage

Conversely, plasma collection is growing rapidly:

  • 867,127 liters of plasma for fractionation delivered in 2024 (+4.8%)
  • +1.4 % plasma donors in one year

This growth supports the national strategy “Ambition Plasma”, with an ambitious goal:

1.4 million liters of plasma collected per year by 2028

To reach this target, EFS is:

• Progressively shifting from whole blood to plasma donations,
• Opening new donation centers and time slots,
• Expanding remote medical supervision (tele-assistance) to facilitate apheresis donations.

A strong and encouraging donor engagement

In 2024:

  • 1,506,534 donors – including 17 % new donors
  • 29 % under 30 years old – a promising new generation of donors
  • A strong sense of commitment that secures the future of blood and plasma supply

The generational renewal is a key success factor for sustaining the transfusion system in the years to come.

A structural shift

2024 confirms a deep transformation:

  • Fewer red blood cell transfusions
  • More plasma collected, better utilized, and more strategic than ever

A crucial evolution to meet therapeutic needs, strengthen the national supply of plasma-derived medicines, and support France’s health sovereignty.

What’s next?

How can we accelerate this transition while maintaining donor loyalty and the right balance between all blood components?

I’d love to hear your insights, experiences, and perspectives.”

Transfusion

 

Stay updated with Hemostasis Today.

French Transfusion Health Hematology Hemostasis Hemostasis Today Maxime Dely Medicine 𝗣𝗹𝗮𝘀𝗺𝗮 𝗿𝗲𝗱 𝗯𝗹𝗼𝗼𝗱 𝗰𝗲𝗹𝗹𝘀 Therapeutic Apheresis and Cell Therapy thrombosis transfusion
NewsFeed